Evidence map›Paper›PMID 24982601›Full record

ArticleJournal of the International Society of Sports Nutrition2014

Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial.

Franchek Drobnic, Joan Riera, Giovanni Appendino, Stefano Togni, Federico Franceschi, Xavier Valle, Antoni Pons, Josep Tur

Open access · goldAbstract read
In one paragraph

Article in Journal of the International Society of Sports Nutrition, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 10 pooled it
9.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 10 syntheses or guidelines pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Antioxidants for preventing and reducing muscle soreness after exercise.The Cochrane database of systematic reviews · 2017
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Evaluation of the Impact of Different Doses ofBioMed research international · 2021
    Trial
  18. Trial
  19. Trial
  20. Trial

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Franchek DrobnicOlympic Training Centre (CAR), Barcelona, Spain.
Joan RieraOlympic Training Centre (CAR), Barcelona, Spain.
Giovanni AppendinoUniversità degli Studi del Piemonte Orientale, Novara, Italy.
Stefano TogniIndena s.p.a., Milano, Italy.
Federico FranceschiIndena s.p.a., Milano, Italy.
Xavier ValleUniversity of Barcelona, School of Sports Medicine, Medical Services, FCBarcelona, Spain.
Antoni PonsDepartment Biologia Fonamental i de la Salut, University of Illes Balears, Mallorca, Spain.
Josep TurDepartment Biologia Fonamental i de la Salut, University of Illes Balears, Mallorca, Spain.
Agpyme (Spain) · ESIndena (Italy) · ITServei de Salut de les Illes Balears · ESFC Barcelona · ESUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDelayed onset muscle soreness (DOMS) due to eccentric muscle activity is associated with inflammatory responses and production of reactive oxygen species (ROS) that sustain both inflammation and oxidative stress. Curcumin, a powerful promoter of anti-oxidant response, is one of the best-investigated natural products, and is now commercially available as a lecithin delivery system (Meriva®, Indena SpA, Milan) with improved bio-availability. The aim of this study was to test whether curcumin could attenuate damage from oxidative stress and inflammation related to acute muscle injury induced by eccentric continuous exercise.

methodsThis was a randomised, placebo-controlled, single-blind pilot trial. Twenty male healthy, moderately active volunteers were randomised to curcumin given as the Phytosome® delivery system 1 g twice daily (200 mg curcumin b.i.d.) or matching placebo. Supplementation was initiated 48 hours prior to a downhill running test and was continued for 24 hours after the test (4 days in total). Muscle damage was quantified by magnetic resonance imaging, laboratory tests and histological analyses on muscle samples obtained 48 hours after the test. Patient-reported pain intensity was also recorded.

resultsSubjects in the curcumin group reported less pain in the lower limb as compared with subjects in the placebo group, although significant differences were observed only for the right and left anterior thighs. Significantly fewer subjects in the curcumin group had MRI evidence of muscle injury in the posterior or medial compartment of both thighs. Increases in markers of muscle damage and inflammation tended to be lower in the curcumin group, but significant differences were only observed for interleukin-8 at 2 h after exercise. No differences in markers of oxidative stress and muscle histology were observed.

conclusionsCurcumin has the potential for preventing DOMS, as suggested by its effects on pain intensity and muscle injury. Larger studies are needed to confirm these results and further clarify the mechanism of action of curcumin.

Indexed as

CurcuminDOMSMeriva®Sport nutrition

Identifiers

PMID24982601
PMCPMC4074833
OpenAlexW2132666134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.